However, studies are ongoing to expand the potential therapeutic benefits of CGRP antagonism in patients with chronic visceral pain, trigeminal neuralgia, fibromyalgia, peripheral neuropathy, and opioid tolerance. This evidence concerns the gene CALCA and fibromyalgia.